Fitness of Leishmania donovani Parasites Resistant to Drug Combinations
Open Access
- 7 April 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 9 (4) , e0003704
Abstract
Drug resistance represents one of the main problems for the use of chemotherapy to treat leishmaniasis. Additionally, it could provide some advantages to Leishmania parasites, such as a higher capacity to survive in stress conditions. In this work, in mixed populations of Leishmania donovani parasites, we have analyzed whether experimentally resistant lines to one or two combined anti-leishmanial drugs better support the stress conditions than a susceptible line expressing luciferase (Luc line). In the absence of stress, none of the Leishmania lines showed growth advantage relative to the other when mixed at a 1:1 parasite ratio. However, when promastigotes from resistant lines and the Luc line were mixed and exposed to different stresses, we observed that the resistant lines are more tolerant of different stress conditions: nutrient starvation and heat shock-pH stress. Further to this, we observed that intracellular amastigotes from resistant lines present a higher capacity to survive inside the macrophages than those of the control line. These results suggest that resistant parasites acquire an overall fitness increase and that resistance to drug combinations presents significant differences in their fitness capacity versus single-drug resistant parasites, particularly in intracellular amastigotes. These results contribute to the assessment of the possible impact of drug resistance on leishmaniasis control programs. Chemotherapy is currently the only treatment option for leishmaniasis, a neglected tropical disease produced by the protozoan parasite Leishmania. However, first-line drugs have different types of limitations including toxicity, price, efficacy and mainly emerging resistance. The WHO has recently recommended a combined therapy in order to extend the life expectancy of these compounds. The emergence and spread of Leishmania antimonial-resistant parasites have led to a high rate of antimonial failure in India and have raised questions about the selection and propagation risk of drug resistant parasites. The spread of drug-resistant parasites in the field probably depends on their transmission potential, which is influenced by, among other factors, the relative fitness of drug-resistant versus drug-susceptible parasites. In light of this, we have designed experimental studies to determine whether Leishmania donovani parasites resistant to single and combinations of anti-leishmanial drugs present any advantages in their ability to bear the different stress conditions versus a susceptible L. donovani line. Our results suggest that resistant parasites acquire an overall fitness increase and that resistance to drug combinations presents significant differences in their fitness capacity, particularly in intracellular amastigotes.Keywords
This publication has 28 references indexed in Scilit:
- Increased metacyclogenesis of antimony-resistant Leishmania donovani clinical linesParasitology, 2011
- The fitness of antimony-resistant Leishmania parasites: lessons from the fieldTrends in Parasitology, 2011
- Drug combinations for visceral leishmaniasisCurrent Opinion in Infectious Diseases, 2010
- RETRACTED: Leishmania donovani Isolates with Antimony-Resistant but Not -Sensitive Phenotype Inhibit Sodium Antimony Gluconate-Induced Dendritic Cell ActivationPLOS Pathogens, 2010
- LeishmaniaInterferes with Host Cell Signaling to Devise a Survival StrategyJournal of Biomedicine and Biotechnology, 2010
- Peroxidases of TrypanosomatidsAntioxidants & Redox Signaling, 2008
- Genome-wide gene expression profiling analysis of Leishmania major and Leishmania infantum developmental stages reveals substantial differences between the two speciesBMC Genomics, 2008
- Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivoInternational Journal of Antimicrobial Agents, 2007
- Phospholipid Translocation and Miltefosine Potency Require Both L. donovani Miltefosine Transporter and the New Protein LdRos3 in Leishmania ParasitesJournal of Biological Chemistry, 2006
- Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living miceCellular Microbiology, 2004